Format

Send to

Choose Destination
Clin Cancer Res. 2016 Apr 1;22(7):1583-91. doi: 10.1158/1078-0432.CCR-15-1745. Epub 2015 Nov 12.

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.

Author information

1
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri. Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri. cma@dom.wustl.edu mjellis@bcm.edu.
2
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
3
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri. Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri.
4
Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri. The McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri. Department of Genetics, Washington University School of Medicine, St. Louis, Missouri.
5
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri. Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri. The McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri. Department of Genetics, Washington University School of Medicine, St. Louis, Missouri.
6
The McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri.
7
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
8
Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri. The McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri. Department of Genetics, Washington University School of Medicine, St. Louis, Missouri. Division of Genomics and Bioinformatics, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
9
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas. cma@dom.wustl.edu mjellis@bcm.edu.

Abstract

PURPOSE:

This trial was conducted to determine the maximum tolerated dose (MTD) and preliminary efficacy of buparlisib, an oral pan-class I PI3K inhibitor, plus fulvestrant in postmenopausal women with metastatic estrogen receptor positive (ER(+)) breast cancer.

EXPERIMENTAL DESIGN:

Phase IA employed a 3+3 design to determine the MTD of buparlisib daily plus fulvestrant. Subsequent cohorts (phase IB and cohort C) evaluated intermittent (5/7-day) and continuous dosing of buparlisib (100 mg daily). No more than 3 prior systemic treatments in the metastatic setting were allowed in these subsequent cohorts.

RESULTS:

Thirty-one patients were enrolled. MTD was defined as buparlisib 100 mg daily plus fulvestrant. Common adverse events (AE) included fatigue (38.7%), transaminases elevation (35.5%), rash (29%), and diarrhea (19.4%). C-peptide was significantly increased during treatment, consistent with on-target effect of buparlisib. Compared with intermittent dosing, daily buparlisib was associated with more frequent early onset AEs and higher buparlisib plasma concentrations. Among the 29 evaluable patients, the clinical benefit rate was 58.6% (95% CI, 40.7%-74.5%). Response was not associated with PIK3CA mutation or treatment cohort; however, loss of PTEN, progesterone receptor (PgR) expression, or mutation in TP53 was most common in resistant cases, and mutations inAKT1 and ESR1 did not exclude treatment response.

CONCLUSIONS:

Buparlisib plus fulvestrant is clinically active with manageable AEs in patients with metastatic ER(+)breast cancer. Weekend breaks in buparlisib dosing reduced toxicity. Patients with PgR negative and TP53 mutation did poorly, suggesting buparlisib plus fulvestrant may not be adequately effective against tumors with these poor prognostic molecular features.

PMID:
26563128
PMCID:
PMC4818722
DOI:
10.1158/1078-0432.CCR-15-1745
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center